FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy
- PMID: 39910249
- PMCID: PMC12244404
- DOI: 10.1038/s43018-025-00905-6
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy
Abstract
FLASH radiotherapy holds promise for treating solid tumors given the potential lower toxicity in normal tissues but its therapeutic effects on tumor immunity remain largely unknown. Using a genetically engineered mouse model of medulloblastoma, we show that FLASH radiation stimulates proinflammatory polarization in tumor macrophages. Single-cell transcriptome analysis shows that FLASH proton beam radiation skews macrophages toward proinflammatory phenotypes and increases T cell infiltration. Furthermore, FLASH radiation reduces peroxisome proliferator-activated receptor-γ (PPARγ) and arginase 1 expression and inhibits immunosuppressive macrophage polarization under stimulus-inducible conditions. Mechanistically, FLASH radiation abrogates lipid oxidase expression and oxidized low-density lipid generation to reduce PPARγ activity, while standard radiation induces reactive oxygen species-dependent PPARγ activation in macrophages. Notably, FLASH radiotherapy improves infiltration and activation of chimeric antigen receptor (CAR) T cells and sensitizes medulloblastoma to GD2 CAR-T cell therapy. Thus, FLASH radiotherapy reprograms macrophage lipid metabolism to reverse tumor immunosuppression. Combination FLASH-CAR radioimmunotherapy may offer exciting opportunities for solid tumor treatment.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: D.G.K. is a cofounder of and stockholder in XRAD Therapeutics, which is developing radiosensitizers. D.G.K. is a member of the scientific advisory board and owns stock in Lumicell, a company commercializing intraoperative imaging technology. None of these affiliations represent a conflict of interest with respect to the work of this manuscript. D.G.K. is a coinventor on a patent for a handheld imaging device and is a coinventor on a patent for radiosensitizers. None of these patents are relevant to this manuscript. XRAD Therapeutics, Merck, Bristol Myers Squibb and Varian Medical Systems have provided research support to D.G.K. but this did not support the research described in this manuscript. Z.J.R. is listed as an inventor for intellectual property related to genetic testing for brain tumors that is managed by Duke Office of Licensing and Ventures, which is not relevant to this manuscript. The other authors declase no competing interests.
References
MeSH terms
Substances
Grants and funding
- P01 CA257904/CA/NCI NIH HHS/United States
- P50CA190991/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- P50 CA190991/CA/NCI NIH HHS/United States
- K08 CA256045/CA/NCI NIH HHS/United States
- R01 CA241501/CA/NCI NIH HHS/United States
- R01NS106108/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- R01NS094533/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- R35 CA197616/CA/NCI NIH HHS/United States
- R01CA241501/U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
- R01HL106108/U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- R01 NS106108/NS/NINDS NIH HHS/United States
- R01CA241501/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- P30 CA014236/CA/NCI NIH HHS/United States
- R01 HL155198/HL/NHLBI NIH HHS/United States
- R01 NS094533/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
